Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families

Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families

Abstract Background Despite chemo-induction therapy and autologous stem cell transplantation (ASCT), the vast majority of patients with Multiple Myeloma (MM) relapse within 7 years and the disease remains incurable. Adoptive Allogeneic T-cell therapy (ATCT) might be curative for MM, however current...

Full description

Bibliographic Details
Main Authors: S. Yado, G. Luboshits, O. Hazan, R. Or, M. A. Firer
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Bone marrow transplantation
Graft-versus-host disease
Graft-versus-myeloma
Adoptive allogeneic T-cell therapy; T cell–receptor Vβ families;
Online Access:http://link.springer.com/article/10.1186/s40425-019-0776-9

Internet

http://link.springer.com/article/10.1186/s40425-019-0776-9

Similar Items